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Abstract
Gastric cancer (GC) is the third leading cause of cancer-related deaths. More than 80% of the
diagnosis was made at the advanced stages of the disease, highlighting the urgent demand for novel
biomarkers that can be used for early detection. Recently, a number of studies suggest that circulating microRNAs (miRNAs) could be potential biomarkers for GC diagnosis. Cancer-related
circulating miRNAs, as well as tissue miRNAs, provide a hopeful prospect of detecting GC at early
stages, and the prospective participation of miRNAs in biomarker development will enhance the
sensitivity and specificity of diagnostic tests for GC. As miRNAs in blood are stable, their potential
value as diagnostic biomarkers in GC has been explored over the past few years. However, due to
the inconsistent or sometimes conflicting reports, large-scale prospective studies are needed to
validate their potential applicability in GC diagnosis. This review summarizes the current development about potential miRNA biomarkers for GC diagnosis and the obstacles hindering their
clinical usage.
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Introduction
Gastric cancer (GC) is the third most common
cause of cancer-related mortality worldwide, and has
a particularly high incidence in Asian countries including China and Japan. Although the incidence of
gastric cancer has been reduced in certain developed
countries over the past few decades, there are still
over 1 million newly diagnosed cases and 850,000
deaths globally each year. More than 70% of the cases
occurs in developing countries, with 50% occur in
Eastern Asia [1].
Due to the absence of specific early symptoms,
most GCs are diagnosed at advanced stages with no
effective treatment. As the prognosis for GC patients
differs depending on the disease stage at the time of
diagnosis, early detection of GC is crucial. Endoscopic
biopsy is the best way to find GC before presenting
clinic symptoms, however, few patients would like to
undergo endoscopy due to the potential side effects,

including aspiration pneumonia, bleeding, and perforation. Hence, there is an urge need for the discovery of non-invasive early detection biomarkers for GC
patients.
Nowadays, several serum tumor markers have
been used in clinic for several years, such as
α-fetoprotein (AFP), carcinoembryonic antigen (CEA)
and carbohydrate antigens 125 and 19-9(CA 125 and
CA 19-9). However, none of these markers are specific
or sensitive in GC, especially in the early stage. Even
though the combined use of these tumor markers
improves the sensitivity to some extent for the advanced GC, these markers yield inconsistent results
when used for early GC detection [2]. Therefore,
identifying novel sensitive biomarkers for early GC
diagnosis have become a hot research topic worldwide [3, 4, 5].
Despite extensive studies, the exact molecular
http://www.jcancer.org
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mechanisms of GC are still poorly understood. GC
development is a complex, multi-step process involving deregulation of several oncogenic pathways.
These oncogenic signaling pathways can be activated
by some genetic and epigenetic alterations, such as the
aberrant gene methylation, histone modifications and
microRNA regulation. Increasing evidence indicates
that GC is largely governed by complex interactions
between multiple pro- and anti-oncogenic signaling
pathways [6].
MiRNAs are small non-coding RNAs, about
18-24 nucleotides in length that control various biological processes through binding to the 3’ untranslated region (UTR) of mRNAs, and affecting the stability and translation of their target genes. miRNAs
function through miRNA-RNA induced silencing
complex, which binds to specific mRNA targets via
base pairing at the 3′-UTR, leading to translational
repression or degradation of these mRNAs. In addition, miRNAs have also been shown to target mRNAs
in the coding region, 5′-UTR as well as promoter region. This sparked great interests in elucidating the
dynamic roles of miRNA that may play in the development and progression of cancer, and led to the
rapid expansion of this field [7] [8] [9]. According to
miRBase Release 21 (June 2014), 2,588 unique mature
human miRNAs have been identified [5, 6].
Although the biological function of miRNAs has
yet to be fully understood, miRNA analyses indicate
that a wide range of cancers display significantly differential expression profiles compared to normal tissues [10] [11] [12] [13] [14] [15]. Since miRNAs are
gene expression regulators, identification of aberrant
tissue-specific miRNA expression in certain cancer
may provide potential new biomarkers for clinical
diagnosis, evaluation of prognosis, and choice of
treatment [16] [17] [18] [19] [20]. Previous studies have
revealed dozens of miRNAs that play important roles
in gastric tumorigenesis, and might be potential biomarkers [21] [22] [23] [24] [25] [26]. As a potential
biomarker that could be applied in clinical use, the
selected cancer-associated markers, such as miRNA
biomarkers, should be easy to detect, ideally from
body fluids, such as blood. Thus researchers have
devoted to identifying the sensitive miRNA markers
in the blood for GC patients [27] [28] [29] [30] [31] [32].
Circulating miRNAs remain stable after incubation at room temperature for up to 24h or after up to
eight cycles of freeze-thawing [32]. Their stability and
easily testable length (about 22bp) make miRNAs
suitable for being cancer biomarkers. Fortunately,
several circulating miRNAs have been identified,
which are significantly changed in their expression in
GC patients compared to that of normal population
[33] [34] [35].
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Up-regulated circulating miRNAs in GC
In 2010, Tsujiura et al first reported the expression of a group of circulating miRNAs (miR-17-5p,
miR-21, miR-106a, miR-106b and let-7a) were significantly aberrant in plasma of GC patients [36].
MiR-17-5p, miR-21, miR-106a and miR-106b expression were significantly upregulated whereas let-7a
was downregulated in GC patients. Although the
study only included 69 GC patients and 30 healthy
volunteers, it indicated that detection of circulating
miRNAs might provide new complementary tumor
markers for GC patients.
Manuel Valladares-Ayerbes et al [37] analyzed
the microarray expression profiles of the miR-200
family in 160 paired samples of non-tumor gastric
mucosae and GC downloaded from ArrayExpress.
Then they selected miR-200c for validation, and found
a significantly increased blood miR-200c expression
level compared to normal controls by qRT-PCR. Although the specificity was 100% but =sensitivity was
only about 65%. Increased miR-200c expression in
blood were significantly associated with lymph node
metastases and overall survival, but not with other
clinical or pathological characteristics. These data
suggest miR-200c has the potential to be a circulating
diagnostic and prognostic biomarker.
In an E-cadherin / p53 double conditional
knockout (DCKO) mouse model that recapitulates
human diffuse-type GC (DGC) morphologically and
molecularly, Rotkrua and his colleagues [38] demonstrated that DCKO mouse and human GCs are very
similar in miRNA expression patterns. Among the
reported 11 highly expressed serum miRNAs in human GC, four miRNAs, miR-103, miR-107, miR-194,
and miR-210, were verified upregulated in sera of
DCKO mice with both early- and advanced-stage
DGC. Furthermore, the elevation of miR-103 and
miR-194 occurred during the entire progression from
the non-cancer status to the advanced-stage, implying
they could be used as biomarkers in diagnosing the
DGC stage. In addition, a high level of miR-210 may
be a diagnostic biomarker for other cancers, including
diffuse large B-cell lymphoma, pancreatic cancer and
breast cancer.
There are several other reported up-regulated
miRNAs that could be used as potential circulating
biomarkers. For example, Li et al [39] [40] investigated
the expression of miRNA-199a-3p between
pre-operative plasma from EGC (early gastric cancer)
patients and healthy controls; and between
pre-operative and post-operative plasma using
qRT-PCR. They found that the expression of plasma
miRNA-199a-3p in EGC patients was significantly
higher than that of healthy controls and gastric precancerous diseases (GPD) patients. In addition, the
http://www.jcancer.org
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expression of miRNA-199a-3p in plasma was significantly decreased in the post-operative patients. The
AUC of miRNA-199a-3p expression in plasma for
EGC diagnosis was much higher than that of combined tumor markers. Therefore, plasma miRNA-199a-3p may serve as a prognostic biomarker for
EGC. Furthermore, the expression of miRNA-199a-3p,
miR-221, miR-106b and miR-20a are significantly elevated in plasma of GC patients.
Fu Z et al [29] analyzed the level of circulating
miR-222 in plasma of GC patients using qRT-PCR in
114 GC patients, compared to 36 chronic atrophic
gastritis (CAG) patients and 56 healthy controls. The
results showed that the expression of circulating
miR-222 in plasma was significantly upregulated in
GC compared with either CAG or healthy controls.
And its expression level was significantly correlated
with clinical stages and lymph nodes metastasis. The
ROC curve analysis revealed that miR-222 had considerable diagnostic accuracy, yielded an AUC of
0.850 with 66.1 % sensitivity and 88.3 % specificity in
discriminating GC from healthy controls. Moreover,
Kaplan-Meier analysis demonstrated a correlation
between increased circulating miR-222 level and reduced disease-free survival and overall survival.
These findings suggested that circulating miR-222 in
plasma might be a potential and useful non-invasive
biomarker for the early detection and prognosis of
GC.
MiR-106b-25 has been studied in several cancers.
Zhang R et al [41] tested miR-106b-25 expression in 40
post-operative and 20 pre-operative plasma samples
of GC patients and explored the correlation between
MiR-106b-25 and related clinical pathological factors.
The expression of miR-106b-25 cluster in plasma was
significantly correlated with tumor size, pathological
type and TNM stage in GC patients. What's more, the
three members of miR-106b-25 cluster expressed consistently at a high level both in tissue and plasma.
Considering the relationship between three miRNAs
and some clinical pathological factors, it was implied
that miR-106b-25 could be the potential tumor biomarker for diagnosis and prognosis for GC patients.
In another study, circulating miR-122 and -192
expression levels were analyzed in GC patients with
qRT-PCR [42]. They found that plasma miR-122 expression was significantly decreased while miR-192
was increased in GC/DM samples compared to normal or benign controls. The similar expression pattern
of these two miRNAs was observed in patients with
post-distant metastases compared to those with
pre-distant metastases. . Dysregulation of miR-122
expression but not miR-192 expression in plasma was
associated with more favorable prognosis for GC. This
suggests that that evaluation of circulating miR-122
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and miR-192 expression levels could potentially help
early detection of DM in GC.
Tsujiura M et al [43] hypothesized that miR-18a,
which is a member of miR-17-92 cluster and has been
reported as highly expressed in GC tissues, could be
used as a novel plasma biomarker in GC patients. The
study showed that miR-18a expression in both biopsy
tissues and plasma was significantly higher in GC
patients than in healthy controls, with AUC value of
0.8059. The plasma miR-18a levels were significantly
reduced in post-operative plasma compared to that of
preoperative samples. In a miR-18a overexpressing
cell line, the miR-18a concentration in cultured medium was increased, suggesting that miRNA-18a
might be released from cancer cells into the surrounding environment. Therefore, circulating
miR-18a could be a useful biomarker for screening GC
and monitoring tumor dynamics.
There were many other circulating miRNAs reportedly increased in GC, such as miR-21 [44] [45] [46]
[47] [48] [49] [50] [51], miR-221 [52], miR-378 [53],
miR-451 and miR-486 [54]. Several studies found that
miR-421 was overexpressed in GC [55] [56] [57], and
the positive detection rate of miR-421 is higher than
that of serum CEA. Since the serum concentration of
miR-421 has higher sensitivity and specificity than
CEA [58], miR-421 may serve as an efficient early diagnostic biomarker. Along with the in-depth study
about the circulating miRNAs associated with GC,
more miRNAs would be found to have the potential
of being diagnosis biomarkers in GC.

Down-regulated circulating miRNAs in
GC
Besides the up-regulated miRNA, there were
also down-regulated miRNA in GC.
Multiple groups reported and validated that
miR-375 was down-regulated in GC [59] [60, 61] [62].
miR-375 was significantly down-regulated in distal
gastric adenocarcinoma tissues as well as in serum
[63]. At a normalized cutoff of 0.218, miR-375 yielded
a receiver operating [62] characteristic (ROC) area
under the curve (AUC) of 0.835 with a specificity of
80% and a sensitivity of 85%, in the discrimination of
distal gastric adenocarcinoma from control tissues,
while the level of miR-31 was significantly lower [64]
[65]. Another study found that miR-195-5p was significantly down-regulated in GC, indicating
miR-195-5p may serve as a novel tumor suppressor
miRNA involving gastric carcinogenesis [66].
There were over 20 down-regulated circulating
miRNAs reported till today, yet their clinical utility
needs to be validated [67].

http://www.jcancer.org
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Table 1. Up-regulated circulating miRNA in GC
Author
Tsujiura [36]

miRNA
miR-17-5P
miR-21
miR-106a
miR-106b
miR-200c

Samples
69 GC patients, 30 healthy
volunteer

Methods
qRT-PCR

67 blood samples (52 stage I-IV
GC patients and 15
controls
DCKO rat model, 5
DGC-bearing mice vs 5 controls
30 EGC patients and 70 controls
114 GC patients , 36 CAG
patients, 56 healthy controls
40 post-operative and 20
pre-operative plasma samples

qRT-PCR

12 pairs of samples

qRT-PCR

Tsujiura M [43] miR-18a

104 GC patients, 65 healthy
volunteers

qRT-PCR

Wu J [58]

miR-421

90 GC patients and 90 controls qRT-PCR

Song J [48]

miR-21

103 GC patients

Manuel Valladares-Ayerbe
s [37]
Rotkrua [38]
miR-103, -107, 194, -210
Rotkrua [39,40] miR-199a-3p
Fu Z [29]

miR-222

Zhang R [41]

miR-106b-25
cluster(miR-106b,
-93, -25)
miR-192

Chen Q [42]

TaqMan q
RT–PCR, miRNA
microarrays
miRNA microarray, qRT-PCR
qRT-PCR

Proportion
miR-17-5p(P=0.006, ),miR-21 (P=0.05), miR-106a
(P=0.008) and miR-106b (P<0.001, AUC=0.721)
higher in GC, let- 7a (P=0.002) lower, ratio of
miR-106a/let-7a AUC= 0.879
AUC-ROC was 0.715(P=0.012), Sensitivity 65.4%,
specificity 100%, accurate rate 73.1%

Usage
Early diagnosis

miR-103, miR-107, miR-194, miR-210 (P=0.045,
0.004, 0.004 and 0.030) was higher in DCKO
mouse sera
AUC for EGC 0.818,sensitivity 76%, specificity
74%, and accuracy 75%,P<0.001
AUC 0.850, sensitivity 66.1 %, specificity 88.3 %

Early diagnosis of
DGC

TaqMan qRT–PCR Change fold were 2.51(miR106b), 2.32(miR-93),
2.10(miR-25)respectively, correlated with tumor
size, bomman type and TNM stage(P<0.05)

qRT-PCR

AUC for plasma miR-192 was 0.732(95% CI
0.623-0.841,P<0.01)
Higher miR-18a in GC than controls,
P<0.0001,ROC value 0.8059

Diagnostic, prognostic biomarker

Diagnostic biomarker
for EGC
Early detection and
prognosis of GC
Diagnosis and prognosis biomarker

Early diagnosis

Higher sensitivity and specificity than CEA and
CA-125 in GC diagnosis
Increased level of miR-21 associated with tumor
size and pT stages(r=0.2633,P=0.0072)

Screening GC and
monitoring tumor
dynamics
Early diagnosis
Indicator for tumor
burden in GC patients, biomarker for
therapy

Table 2. Down-regulated circulating miRNA in GC
Author
Chen Q[42]

miRNA
miR-122

Zhang WH[68]

miR-375

Gorur A[71]

miR-195-5p

Samples
12 pairs of blood
samples

20 blood samples
from GC patients
and 190 volunteers

Methods
qRT-PCR
Microarray,
qRT-PCR
q RT-PCR

Difficulties in the application of circulating miRNAs as GC diagnostic biomarkers
1. Suitable internal reference genes
The prospective studies about circulating miRNAs suggested a bright future for the development of
non-invasive biomarkers for GC molecular diagnosis.
However, the accurate identification of miRNA-based
biomarkers has been a significant challenge and is still
difficult in clinical settings. Measurement of circulating miRNAs may be influenced by a number of factors, including amount of starting materials, methods
of sample collection, RNA extraction, etc. . Among the
reported potential circulating miRNAs, some of them
were detected in serum, others in plasma. One of the
meta-analyses suggested that plasma-based miRNA
assay reached a higher accuracy compared to serum-based one for GC [68]. Meanwhile, technical
challenges exist in measuring circulating miRNA.

Proportion
AUC for plasma miR-122 was
0.808, 95% CI 0.712-0.905,P<0.01
miR-375 ROC 0.835, specificity
80%, sensitivity 85%
miR-195-5p down-regulated 13.3
fold, P<0.05

Usage
miR-122 down-regulated in GC, higher
miR-122 may indicate a favorable prognosis
Biomarker for distal GC
miR-195-5p was a tumor suppressor miRNA
and may contribute to gastric carcinogenesis

Because of the relatively low expression of RNA
isoforms in serum and plasma, conventional methods
of spectrophotometry are not reliable to control for
total amount of RNA extracted from samples; and the
high concentration of miRNAs in blood cells can easily confound results if these are not removed carefully
and/or cellular lysis is not prevented [69].
In a research on internal control small RNA U6
expression, Xiang M et al [70] found that the expression level of U6 was gradually decreased after 1, 2,
and 4 cycles of freezing and thawing. It is reasoned to
doubt that the expression of miRNA markers may not
be stable and could be fluctuant under different cycles
of freezing and thawing. More thorough research and
standard procedure of sample collection should be
established before these novel biomarkers being used
in practice.
Furthermore, age and sex may be confounding
variables when miRNAs were measured from blood
samples. Meder B et al [71] explored the impact of age
and sex on miRNAs in a cohort of 109 physiologically
http://www.jcancer.org
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unaffected individuals whose blood miRNAs was
characterized by microarray technology. They also
investigated an independent cohort from a different
institution consisting of 58 physiologically unaffected
individuals with similar mean age, but with a smaller
age distribution. The samples were measured with
high-throughput sequencing. They detected 318
miRNAs that were significantly correlated with age
and, after adjustment for multiple testing, 35 of them
remained statistically significant. Regarding sex, 144
miRNAs showed significant dysregulation; however,
no miRNA remained significant after adjustment for
multiple testing. In the high-throughput datasets,
they observed a smaller number of significant associations, mainly as an effect of the smaller cohort size
and age distribution. They concluded that age distribution of individuals recruited for case-control studies needs to be carefully considered, whereas sex may
be less confounding. Thus the possible influence of
age or sex should be considered when the expression
of circulating miRNAs is being assessed.
The main method of miRNA detection was real-time quantitative Polymerase Chain Reaction
(qPCR). This effective technology could significantly
amplify the tiny content of miRNAs to an easily detectable level. There are numerous challenges to
achieve sufficient sensitivity and specificity in the
measuring circulating miRNAs, particularly in selecting appropriate normalization controls. There is
however currently no agreement on this issue, which
makes it impossible to compare the results from different labs or platforms. Therefore, it is essential to
develop an effective and uniformed normalization
strategy in evaluating circulating miRNA expression
levels. One of the popular and relatively accurate
strategies is to use a stable reference gene or a set of
gene signatures (s) to evaluate circulating miRNA
expression. Otherwise the data may not be reliable.
One example is to use the same amount of the starting
total RNA, however, due to the low yield of total RNA
from serum or plasma, it is hard to measure the RNA
yield and quality accurately with the available methods [72].
Despite the most common controls, U6 and
miR-16 are used as internal control for miRNA quantification, Xiang M et al [70] found large fluctuations
in U6 expression from their microarray-based serum
miRNA profiling on a number of cancer patients and
normal controls. They also demonstrated that the expression of U6, miR-16 and miR-24 in serum was
subjected to different freeze-thaw cycles. Therefore,
U6 may not be an ideal internal control for circulating
miRNAs.
In order to identify stable controls for circulating miRNA quantification, a global circulating miR-
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NA profiling study was performed using healthy
controls, chronic hepatitis B, cirrhosis and a variety of
cancer patients The most stable controls were selected
by a number of programs, such as GeNorm,
NormFinder, and coefficient of variability (CV). Seven
candidates
miRNAs,
miR-1225-3p,
miR-1228,
miR-30d, miR-939, miR-940, miR-188-5p, and miR-134
were identified, and validated by qPCR, along with
the commonly used four other controls, miR-16,
miR-223, let-7a, and RNU6B using an independent
cohort. miR-1228 (CV = 5.4%) turns out to be the most
stable one among all tested. Interestingly, miR-1228 is
involved in metabolism-related signal pathways and
organ morphology by Ingenuity Pathway Analysis
(IPA), which suggests that miR-1228 may be a
housekeeping miRNA gene. The stable expression of
miR-1228 in the blood may qualify it as a promising
control for circulating microRNAs quantification [73].
Another study indicated that miR-93 may be a useful
internal control for serum miRNA analysis in GC [34].
Chen X et al. [74] screened and validated the
reference genes using a strategy by combining the
Illumina’s sequencing by synthesis (SBS) technology,
qPCR, literature screening and statistical analysis. . A
panel of let-7d, let-7g and let-7i was developed as a
reference set for circulating miRNA normalization,
and subsequently validated across numerous healthy
controls and patients, and was demonstrated to be
statistically better than the commonly used reference
set, such as U6, RNU44, RNU48 and miR-16. Because
of the variations of the internal control genes, special
attention should be paid when comparing the diagnostic value of the circulating miRNAs.

2. High specificity and sensitivity of circulating
miRNAs
As ideal diagnostic biomarkers, circulating
miRNAs should be specific enough to distinguish GC
from other diseases, and sensitive to be detectable.
However, most of the reported circulating miRNAs
with aberrant expression profile in GC were also observed in other cancers. For example, the expression
of miR-200 family was dysregulated not only in GC
[75], but also in colorectal carcinoma [76] [77] [78],
hepatocellular carcinoma [79], anaplastic thyroid
cancer [80], ovarian cancer [81] [82], breast cancer [83]
[84], prostate cancer [85], and pancreatic cancer [86].
MiR-222 was classified as oncomiR both in GC and
hepatitis B-related hepatocellular carcinoma [87].
Even the contradictory results were found on the
same miRNA in GC. For example, miR-199a-3p was
found both up-regulated [40] and down-regulated
[88] in GC in different studies.
Since there is no single circulating miRNA that
could be used to diagnose GC till today, the combinahttp://www.jcancer.org
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tion of several miRNAs has been presented by some
researchers. In a meta-analysis research, a total of 107
studies from 42 articles were included about the potential circulating miRNAs in GC and colorectal cancer (CRC). The overall analysis of all GI cancers
showed that circulating miRNAs have a relatively
good diagnostic performance. In addition, single-miRNA assay displayed a relatively low diagnostic performance, while multiple-miRNA assay significantly improved the diagnostic accuracy for GC and
CRC [68]. Therefore, a signature of miRNAs may
serve as promising biomarkers for the diagnosis of
GC.
In another meta-analysis conducting to assess
the diagnostic value of circulating miRNAs for GC in
Asian population, the literature search was carried
out in databases (PubMed, Embase, Web of Science,
The Cochrane Library, and CNKI) and other sources
using combinations of keywords relating to GC,
miRNAs, and diagnosis. The values of sensitivity,
specificity, positive likelihood ratios (PLR), negative
likelihood ratios (NLR), and diagnostic odds ratio
(DOR) reported in individual studies were pooled
using random-effects models. Potential sources of
heterogeneity were assessed with subgroup and meta-regression analyses. The summary receiver operating characteristic (SROC) curve and the AUC were
used to assess the diagnostic accuracy of miRNAs.
This meta-analysis included 1,279 patients with GC
and 954 healthy controls from 20 publications. The
pooled sensitivity, specificity, PLR, NLR, DOR, and
AUC were 0.78, 0.80, 4.0, 0.28, 14, and 0.86, respectively. Subgroup analyses showed that early stages (I
and II) GC were more easily detected than later stages, and that multiple miRNAs assays were more accurate than single miRNA assays [89]. This meta-analysis concluded that miRNAs had a higher diagnostic value for GC in early stages (I and II) than in
late stages, and multiple miRNAs assays had a better
diagnostic value than single miRNA assays.
Besides the meta-analysis, a panel of five miRNAs (miR-16, miR-25, miR-92a, miR-451 and
miR-486-5p) seemed to show consistently high level
expression in GC patients’ plasma [31]. This 5-miRNA
panel may serve as a potential non-invasive biomarker in early GC detection.
The combination of miRNA markers could consist of both up-regulated and down-regulated miRNAs. For example, overexpressed miR-223, miR-21
and underexpressed miR-218 in GC patients yield the
AUC values of 0.9089, 0.7944, and 0.7432, respectively,
while the combined ROC analysis reveals the highest
AUC value of 0.9531 in discriminating GC patients
from healthy controls [44]. This suggests that a cluster
of miRNAs would be a better diagnostic biomarker
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than single miRNA, with much higher sensitivity,
specificity, and accuracy.

Conclusions
The search for better non-invasive biomarkers
for the diagnosis of GC has led to the investigation of
aberrant circulating miRNAs in plasma or serum. The
expression level of miRNAs could be easily detected
using qRT-PCR. The studies demonstrated that higher
sensitivity and specificity can be achieved by circulating miRNAs as compared to other commonly used
biomarkers. Furthermore, the combination of several
miRNAs reached higher specificity and sensitivity
than single miRNA. However, the standard protocol
of sample treatment and the suitable internal controls
should be further established to make the detection
comparable before the miRNA biomarkers being fully
utilized in clinical practice.
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